Abstract
Dose-response curves of the effect of angiotensin I (A-I) infusion on diastolic blood pressure were constructed before and 3 h following single oral doses of the angiotensin-converting enzyme (ACE) inhibitor cilazapril (1.25 to 30 mg) in six normal male subjects. Cilazapril shifted the A-I dose-response curves dose dependently rightward; Schild-plot analysis indicated a competitive antagonism by cilazapril with an apparent Ki-dose of about 0.6 mg.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Belz G. G., Essig J., Wellstein A. Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol. 1987 Feb;9(2):219–224. doi: 10.1097/00005344-198702000-00015. [DOI] [PubMed] [Google Scholar]
- Belz G. G., Lange H., Tschollar W., Neis W. Cilazapril bei essentieller Hypertonie. Eine placebokontrollierte Doppelblindstudie zur Dosisfindung. Med Klin (Munich) 1986 Jul 18;81(15-16):524–529. [PubMed] [Google Scholar]
- GADDUM J. H. Theories of drug antagonism. Pharmacol Rev. 1957 Jun;9(2):211–218. [PubMed] [Google Scholar]
- Hassall C. H., Kröhn A., Moody C. J., Thomas W. A. The design of a new group of angiotensin-converting enzyme inhibitors. FEBS Lett. 1982 Oct 18;147(2):175–179. doi: 10.1016/0014-5793(82)81036-3. [DOI] [PubMed] [Google Scholar]
- Natoff I. L., Nixon J. S., Francis R. J., Klevans L. R., Brewster M., Budd J., Patel A. T., Wenger J., Worth E. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):569–580. doi: 10.1097/00005344-198505000-00025. [DOI] [PubMed] [Google Scholar]
- Ondetti M. A., Cushman D. W. Enzymes of the renin-angiotensin system and their inhibitors. Annu Rev Biochem. 1982;51:283–308. doi: 10.1146/annurev.bi.51.070182.001435. [DOI] [PubMed] [Google Scholar]
- STEPHENSON R. P. A modification of receptor theory. Br J Pharmacol Chemother. 1956 Dec;11(4):379–393. doi: 10.1111/j.1476-5381.1956.tb00006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strittmatter S. M., Snyder S. H. Characterization of angiotensin converting enzyme by [3H]captopril binding. Mol Pharmacol. 1986 Feb;29(2):142–148. [PubMed] [Google Scholar]
- Wellstein A., Palm D., Pitschner H. F., Belz G. G. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol. 1985;29(2):131–147. doi: 10.1007/BF00547412. [DOI] [PubMed] [Google Scholar]